Onconetix, Inc. ONCO NASDAQ · Healthcare · United States
$2.85 -9.81% -$0.31
Summary
28 / 100 · Bulios Score
What speaks for it
- It earns 44 USD a year on every 100 USD of invested capital.
- It holds more cash than debt: $2.74M against $105.1K.
What to watch
- The company made a loss over the last 12 months.
- It passes only 3 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedThe company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
There is not enough revenue history yet to say how fast it grows.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $33.0M.
Profitability in detailIs it financially healthy?
YesOver the last 12 months it spent more cash than it brought in. It holds more cash than debt. The debt score is low because of the debt-to-equity ratio.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 1
- Hold 1
- Sell 0
No analyst has published a price target.
50% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- License 100%
By region
- European Union 100%
License brings in 100% of revenue.
Segments in detail